Kamada Ltd
KMDAKamada Ltd (KMDA) is an Israel-based biopharmaceutical company specializing in the development, manufacturing, and commercialization of plasma-derived protein therapeutics for the treatment of various medical conditions, such as rare diseases and inflammatory disorders. The company's products are based on plasma proteins, including Alpha-1 antitrypsin, used for treatment and research purposes. Kamada leverages its proprietary manufacturing platform to produce plasma-derived therapies and expand its portfolio in the biopharmaceutical space.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 7, 2026 | $0.25 | 2026-03-23 | 2026-03-23 |
| April 7, 2025 | $0.20 | 2025-03-17 | 2025-03-17 |
Dividends Summary
- Consistent Payer: Kamada Ltd has rewarded shareholders with 2 dividend payments over the past 1 years.
- Total Returned Value: Investors who held KMDA shares during this period received a total of $0.45 per share in dividend income.
- Latest Payout: The most recent dividend of $0.25/share was paid 102 days ago, on April 7, 2026.
- Yield & Schedule: KMDA currently pays dividends yearly with an annual yield of 3.55%.
- Dividend Growth: Since 2025, the dividend payout has grown by 25.0%, from $0.20 to $0.25.
Company News
Kamada Ltd. announced FDA approval of its new in-house Rapid Fluorescent Focus Inhibition Test (RFFIT) laboratory in Beit Kama, Israel. The facility will enhance quality control and testing capabilities for the company's rabies immunoglobulin products KEDRAB and KAMRAB, which generated over $70 million in 2025 sales. The laboratory represents a s...
Kamada Ltd., a global biopharmaceutical company specializing in plasma-derived therapies, announced it will release its first quarter 2026 financial results on May 13, 2026, followed by a management conference call. The company operates three FDA-approved plasma collection centers in Texas and focuses on growth through its commercial portfolio of...
Kamada Ltd. announced FDA approval of its San Antonio, Texas plasma collection center following an on-site inspection in February 2026. The 11,100 square foot facility has a planned capacity of approximately 50,000 liters per year and is expected to generate $8-10 million in annual revenues from normal source plasma sales at full capacity. The ce...
Kamada reported strong financial performance in Q3 2025, with revenues of $47.0 million (up 13% year-over-year) and adjusted EBITDA of $11.7 million (up 34%). The company reiterated its full-year revenue guidance of $178-$182 million and continues to focus on business development and plasma collection operations.
Kamada Ltd. will release its Q3 and nine-month financial results on November 10, 2025, and will host an investment community conference call to discuss the results.
